Originally organized around commercializing the University of Conneticut and OSCIs wireless, needle-implantable, miniaturized (0.5 x 0.5 x 5 mm) sensor platform for real time, continuous glucose monitoring, Biorasis has alsoben working towards outfitting its sensor platform to monitor other bio-analytes in the body that are important in other disorders such as cardiovascular, cancer, liver, kidney abnormalities, stroke and epilepsy. In addition to two smaller grants and awards to support that effort, in the more recent past - December 2018 - the firm has been in receipt of a substantial award for related work from the Leona M. and Harry B. Helmsley Charitable Trust .
